About: http://data.cimple.eu/news-article/474288469a9351ac4b8c6ae25ebe98e1155eca3059579d08191e17c9

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/474288469a9351ac4b8c6ae25ebe98e1155eca3059579d08191e17c9 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	US scientists are developing a strain of the coronavirus that could be used to deliberately infect volunteers in so-called "challenge studies," a government agency said Friday. The work is preliminary and the government is continuing to prioritize randomized clinical trials of vaccine candidates, the National Institute for Allergies and Infectious Diseases (NIAID) said. Several of these have entered their final stages, including the vaccines developed by Moderna, Pfizer and AstraZeneca. But NIAID has nonetheless "begun efforts to manufacture a strain that could be used to develop a human challenge model, if needed," it said in a statement. In normal clinical trials, volunteers receive either a medicine or a placebo and their health is then followed over the course of months of years. Scientists look for how well the vaccine or treatment worked when the person was naturally exposed to the pathogen. A quicker way to test whether a drug works is by deliberately infecting volunteers, as has been done in the past for influenza, malaria, typhoid, dengue fever, and cholera. In the US, advocacy groups like 1DaySooner support challenge studies for COVID-19, but the subject is controversial because of how serious the disease can be and because its effects aren't fully understood. NIAID said it would probably reach a decision toward the end of 2020, when the late-stage clinical trials that are underway start reporting their results. This would help it determine whether challenge studies are needed, safe and ethical, it added. David Diemert, the director of George Washington University's vaccine trial research unit who is overseeing a trial of Moderna's vaccine in the US capital, told AFP he did not think challenge trials were appropriate for COVID-19. "I think they're a critical tool, but only under the right circumstances," he said. Diemert is himself leading a challenge trial into a hookworm vaccine. But he said that for COVID-19, "we don't have a very clear understanding of who is at risk of developing severe disease and we have no treatment that is guaranteed to cure someone if they do develop severe disease." There's also enough widespread community transmission in the US -- the worst hit country in the world with 5.3 million confirmed cases -- to mean challenge trials are not necessary, he added. ia
schema:headline	US developing coronavirus strain for human 'challenge' trials
schema:mentions	Typhoid fever Pathogen Cholera Agence France-Presse Placebo Medication National Institute of Allergy and Infectious Diseases Malaria Dengue fever Allergy Ia (cuneiform) AstraZeneca Influenza Pfizer Vaccine Severe acute respiratory syndrome coronavirus 2 Hookworm vaccine George Washington University
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-08-14 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	neutral sentiment
http://data.cimple...readability_score	81 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software